Finland· FI-REL-REL7894
Panzynorm
A multienzyme - lipase, protease etc product, registered in Finland by Nordmark Arzneimittel GmbH & Co. KG. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Multienzyme - lipase, protease etc is registered in 11 of 19 countries.
Countries holding a registration under ATC A09AA02 (multienzyme - lipase, protease etc), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Multienzyme - lipase, protease etc · ATC A09AA02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Manufacturer
- Nordmark Arzneimittel GmbH & Co. KG
- Country
- Finland (FI)
- ATC code
- A09AA02
- ATC class
- Multienzyme - Lipase, Protease etc
- Defined daily dose
- 240 TSD, FIP
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for multienzyme - lipase, protease etc.
Graded by severity as the source publishes them — 20 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Multienzyme - lipase, protease etc · interactions on record
20 records
- 20 moderate
Most severe, free to view
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Calcium carbonateA02AC01moderate
- MagaldrateA02AD02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under A09AA02
Multienzyme - lipase, protease etc, as other registers publish it.
- BelgiumAnkreta 10000 UAllgen Pharmaceuticals
- BelgiumAnkreta 25000 UAllgen Pharmaceuticals
- FinlandCombizymSankyo Pharma GmbH
- FinlandCombizym CompSankyo Pharma GmbH
- FinlandCombizym ForteSankyo Pharma GmbH
- SwitzerlandCombizym, DragéesBridging Pharma GmbH
- CanadaCOTAZYMORGANON CANADA INC.
- CanadaCOTAZYM ECS 20ORGANON CANADA INC.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f53aea02-0246-41e6-9818-7693b072866c GET /v1/drugs/f53aea02-0246-41e6-9818-7693b072866c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "4",
"form": "tabletti",
"route": null,
"ddd_unit": "ED",
"strength": null,
"atc_label": "useita entsyymejä (lipaasi, proteaasi jne.) sisältävät valmisteet",
"ma_number": "4155",
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": null,
"fimea_rel_id": "REL7894",
"authorised_at": "1965-10-05"
}See everything about multienzyme - lipase, protease etc.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.